This weekend, Team Sarepta will gather to support people living with neuromuscular diseases by participating in the annual Muscular Dystrophy Association (MDA) Muscle Walk of Massachusetts. For our colleague Shawn Marlow, co-lead of Sarepta’s walk team, this event holds extra special meaning. It’s not only an opportunity for Sarepta to demonstrate the company’s mission but also a nod to his great-grandfather, who began fundraising for the #Duchenne community back in the early 1950s. Shawn's great-grandfather was a South Boston firefighter with a big heart and a knack for getting things done. In 1952, he rallied his fellow firefighters to pick up their boots, stand on street corners and go door-to-door to raise money for a local family whose two sons lived with Duchenne muscular dystrophy. In the years since, firefighters across the nation have filled boots and raised hundreds of millions in donations for the MDA. Today, Shawn sees parallels between his work at Sarepta and his great-grandfather’s roll-up-his-sleeves approach. This event, in particular, gives Sarepta employees a chance to show up for the community in a new way. We invite you to read more about Shawn's story and its connection to our #OneSarepta walk team in our Newsroom -- and we'll see you Saturday! https://bit.ly/3RK4I6n
关于我们
Sarepta Therapeutics, headquartered in Cambridge, Massachusetts, is a global biotechnology company on an urgent mission: engineer precision genetic medicine for rare diseases that devastate lives and cut futures short. We hold leadership positions in Duchenne muscular dystrophy (DMD) and limb-girdle muscular dystrophies (LGMDs), and we currently have more than 40 programs in various stages of development. Our vast pipeline is driven by our multi-platform Precision Genetic Medicine Engine in gene therapy, RNA and gene editing. For information on our Community Guidelines, please visit sarepta.com/community-guidelines. We want to share a reminder with all job seekers and candidates regarding the persistence of recruiting fraud. Please read a message about recruiting fraud and steps you can take to protect yourself here: https://www.sarepta.com/recruiting-fraud
- 网站
-
https://www.sarepta.com
Sarepta Therapeutics的外部链接
- 所属行业
- 生物技术研究
- 规模
- 1,001-5,000 人
- 总部
- Cambridge，MA
- 类型
- 上市公司
地点
Sarepta Therapeutics员工
动态
-
A?well-deserved honor, and no one who deserves it more. We are thrilled to see the Center for Gene Therapy at the Abigail Wexner Research Institute has been named in honor of Dr. Jerry Mendell. His pioneering work in gene therapy is equaled only by his compassion and dedication to the families he has cared for over these past 50+ years. But his influence extends far beyond those under his immediate care; he has profoundly impacted the field of neuromuscular diseases, and we are honored to work alongside him.
?? We are excited to announce the renaming and dedication of the Jerry R. Mendell, MD Center for Gene Therapy at the Abigail Wexner Research Institute, in honor of Dr. Jerry Mendell, a pioneer in the fields of neurology and gene therapy! Dr. Mendell’s work in neuromuscular disease began more than 50 years ago, when he saw his first patient with Duchenne muscular dystrophy (DMD). Thanks in part to his passion to develop new treatments for patients with neuromuscular disorders, he led the pivotal clinical trials for two of the first eight gene therapies approved by the FDA. “I’ve devoted my life to developing therapies with the support of my wife and family that will improve the lives of children and their families. That work could only be accomplished with the support of a dedicated team of professionals and the pioneering spirit of the children and families who participate in clinical studies,” said Dr. Mendell. “I am grateful to have been able to help establish a center for gene therapy at Nationwide Children's Hospital that will continue to change the lives of children well into the future.” Learn more about Dr. Mendell's work: https://bit.ly/4dVMA1T #Research #Neurology #GeneTherapy #LifeAtNCH
-
-
Today, we introduce you to Ryan, a recipient of our 2024-2025 Route 79 academic scholarship for individuals with #Duchenne. He is studying art, music and drama at SUNY New Paltz. We are proud to support his academic goals and recognize his drive and determination for his future. Learn more about the annual scholarship program and this year’s recipients:?https://bit.ly/3TmweXI
-
Today, we introduce you to Ryan, a recipient of our 2024-2025 Route 79 academic scholarship for individuals with #Duchenne. He is studying art, music and drama at SUNY New Paltz. We are proud to support his academic goals and recognize his drive and determination for his future. Learn more about the annual scholarship program and this year’s recipients: https://bit.ly/3TmweXI
-
We’re lighting up red for Duchenne! Our Cambridge HQ is glowing with red lights for World Duchenne Awareness Day. We’re proud to light up the block and show our support for the Duchenne community. #WDAD2024 #LightingUpForDuchenne
-
-
Today is World Duchenne Awareness Day, a day dedicated to raising global awareness of #Duchenne muscular dystrophy. Like we do each year on this day, we’re wearing red to show support for individuals and families impacted by this rare genetic disease. #WDAD2024 #WearRedForDuchenne
-
-
We’re excited to announce the recipients of Sarepta’s 2024-2025 Route 79 Scholarships! Now in its 7th year, this program provides academic scholarships to those living with #Duchenne and siblings in Duchenne families to support post-secondary educational goals. You may wonder what’s the meaning behind the name. The scholarship is titled for the 79 exons in the dystrophin gene impacted by Duchenne, and the unique route traveled by every person with Duchenne. Congratulations to the class of 2024-2025! Meet the recipients in this video and read the press release:?https://bit.ly/3X6ImNG
-
September is #NewbornScreeningAwarenessMonth, a good time to learn about the latest progress in expanding newborn screening programs to include Duchenne. Many families experience a years-long journey to a Duchenne diagnosis, involving visits to many different doctors. In fact, the average time between parents first noticing symptoms and a child receiving a definitive Duchenne diagnosis is typically more than two years. ? Newborn screen-ing is an important step toward eliminating the diagnostic delay in Duchenne.?We applaud ongoing efforts at the federal and state level to consider and facilitate availability of screening for Duchenne nationwide. ?#NBS
-
Important progress in newborn screening right here in our home state of Massachusetts. Duchenne was added to the state’s newborn screening panel as part of a broader maternal health plan, and Massachusetts now joins the other states that have taken this critical step. We applaud state leadership for acting on this important health issue, commend ongoing efforts in additional states and urge federal leaders to follow suit and add screening for Duchenne nationwide.?Because all babies deserve the opportunity for early diagnosis and intervention. https://bit.ly/4fZvG3E? #NewbornScreening
-
-
At Sarepta, we view each day as another 24 hours to stand up for patients, advance technology, challenge convention and drag tomorrow into today. Ethan Jacoby, Vice President, Global Supply Chain, notes that, “dragging tomorrow into today means that sometimes the solution isn’t right in front of us. We have to go out and create something from new.” As we advance science in genetic medicine, we constantly evaluate the full picture and how to ensure products get over the finish line to reach patients. Watch this video to hear more on our innovative supply chain approach.?